SUPPLEMENTARY INFORMATION

Transient Nuclear Lamin A/C Accretion Aids in Recovery from Vapor Nanobubble-induced Permeabilization of the Plasma Membrane

Gaëlle Houthaeve1,2, Gerardo García-Díaz Barriga1, Stephan Stremersch2, Herlinde De Keersmaecker2,4, Juan Fraire2, Jo Vandesompele3, Pieter Mestdagh3, Stefaan De Smedt2,4, Kevin Braeckmans2,4,†, Winnok H. De Vos1,†,*

1Laboratory of Cell Biology and Histology, Department of Veterinary Sciences, University of Antwerp, 2610 Antwerp, Belgium.
2Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, 9000 Ghent, Belgium.
3Center for Medical Genetics, Ghent University, 9000 Ghent, Belgium.
4Centre for Advanced Light Microscopy, Ghent University, 9000 Ghent, Belgium.
† Shared senior authorship

*Corresponding author: Winnok.DeVos@UAntwerpen.be


**Supplementary Table**

(a) Significant DEGs that are shared between VNB vs CTR and heating vs CTR are listed per timepoint (6h, 24h and 48h); (b) Enrichment analysis in the list of significant DEGs for VNB vs CTR and heating vs CTR pointed to three GO biological processes that are shared 6h after treatment (listed in the left column). The significant DEGs that correspond to the commonly enriched biological processes are listed for VNB vs CTR (middle) and heating vs CTR (right).

| Comparison       | Common DEGs                                                                 |
|------------------|-----------------------------------------------------------------------------|
| Heating 6h vs    | DDX39B, PHLD2A, IGFN1, CARMN, RN1Y4, UBC, RN1Y1BI1R, LMNA, TRMT9B, TUBA1C |
| VNB 6h           |                                                                             |
| Heating 24h vs   | PNISR, HSPA1A, DDX58, TAGLN, INCENP, TCEA3, SS18L2, LINCO0094, FAM228B,    |
| VNB 24h          | MALAT1, C3P31, RN1Y1, NDUSF7, PGM5P2, CDC20, CY93A5, MOB3B, SEFL, TMS1,   |
|                  | GP3135, Z8ED2A, PITPMX3, LIN201873, ACTA2, UC713, LEX1H1, TAF3, KMT2B,     |
|                  | PRPF38B, MAB2113, ZNF236, TCIM,                                            |
| Heating 48h vs   | TAGLN, MYL9                                                                 |
| VNB 48h          |                                                                             |

| GO biological process (6h) | VNB                                                                 | Heating                                           |
|---------------------------|---------------------------------------------------------------------|---------------------------------------------------|
| (Striated) muscle cell    | LMNA, PPARA, DDX39B, MYLK3                                           | CSRP2, LMNA, NFATC2, DDX39B, ALPK2                |
| development               |                                                                     |                                                   |
| MyD88-independent TLR     | BIRC3, UBC, IKBG                                                       | BIRC3, PRKCE, UBC                                 |
| signaling                 |                                                                     |                                                   |
| Response to wounding       | CD151, DHFR, HSPB1, LGALS1, PLEC, PPARA, THBS1, TIMP1, C6orf69        | EGFR, ET51, CCN1, DX1, SERPINE1, PRKCE, SDC4,    |
|                           |                                                                     | PROC8, TNF85F12A                                  |

**Table S1.** (a) Significant DEGs that are shared between VNB vs CTR and heating vs CTR are listed per timepoint (6h, 24h and 48h); (b) Enrichment analysis in the list of significant DEGs for VNB vs CTR and heating vs CTR pointed to three GO biological processes that are shared 6h after treatment (listed in the left column). The significant DEGs that correspond to the commonly enriched biological processes are listed for VNB vs CTR (middle) and heating vs CTR (right).
Figure S1. (a) FD10 transfection efficiency and relative mean fluorescence intensity for increasing AuNP concentrations as determined by flow cytometry 2 h after VNB treatment; (b) Cell viability for increasing AuNP concentrations as determined with the metabolic assay Cell Titer Glo 2h or 24h after VNB.
Figure S2. Enriched biological processes from the Gene Ontology (GO) database determined in the list of significant DEGs determined via Metascape for (a) VNB vs CTR at 6h, (b) Heating vs CTR at 6h, (c) VNB vs CTR at 24h, (d) Heating vs CTR at 24h and (e) Heating vs CTR at
48h. More specifically, representatives are shown for clusters of redundant GO biological processes. For each cluster representative the percentage of significant DEGs present in the input list to the total number of genes in that process is plotted as well as the significance (-log corrected p-value) of the enrichment.
**Figure S3.** The chromatin condensation parameter for two different timepoints (6h & 24h) after VNB treatment (VNB) and for the corresponding untreated cells (CTR) in LMNA-WT cells (left) and LMNA-KO cells (right) (***P < 0.001).
Figure S4: (a) The mean nuclear area in LMNA-WT cells at two different timepoints (6h & 24h) after VNB treatment (VNB) and for the corresponding untreated cells (CTR) (*P < 0.05); (b) The mean cell area in LMNA-WT cells at two different timepoints (6h & 24h) after VNB treatment (VNB) and for the corresponding untreated cells (CTR) (***P < 0.001)